CTAD 2022

Alzheimer

Clinical Trials on Alzheimer's Disease



Program

ONSITE + ONLINE

November 29 - December 2, 2022

San Francisco, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD

SUMMARY

Editorial

Dear colleagues,

The field of Alzheimer's disease diagnostics and therapeutics has become one of the most exciting areas in all of medical research. The Clinical Trials on Alzheimer's Disease (CTAD) meeting, being held this November 29-December 2, 2022, promises to continue the excitement!

Why is our field so exciting? Rapid progress in our field has resulted from huge investments by governments into basic science research, followed by more recent huge investments by the private sector into diagnostic, biotech, and pharmaceutical companies. It has only been 15 years since molecular imaging with amyloid PET scans first demonstrated the ability to detect Alzheimer's disease pathology in living people. Now, amyloid PET is widely available, tau PET is being employed by many clinical trials, and very recently blood tests for Alzheimer's disease have shown great promise for screening, and even for diagnosis.

But, without question there is growing evidence that monoclonal antibodies, which remove amyloid plaque, appear to slow cognitive decline. Unfortunately, these treatments are also associated with ARIA, including brain swelling and bleeding in the brain. There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.

These issues will be at the center of the CTAD meeting being held in San Francisco this Fall. Experts from academics and industry will be attending, presenting their data and discussing the pros and cons of various controversial topics. In addition to the formal program there will be extensive networking and discussions around the poster sessions, coffee breaks, formal receptions, and in the hallways.

San Francisco is an especially beautiful city, surrounded by the Pacific Ocean and the San Francisco Bay. Golden Gate Park, and the Presidio are huge parks filled with trees, flowers and historical sites. We have three internationally famous universities, the worlds' largest biotech hub just south of the city, and Silicon Valley further south. Don't forget to include some vacation time and consider visiting the Muir Woods, the Napa Valley, and Carmel/Big Sur to the south.

I'm looking forward to seeing old friends, and making new ones at the CTAD meeting this Fall in beautiful San Francisco.



Dr. Mike Weiner
President of the CTAD22 Scientific Committee

President of the CTAD22 Scientific Committee

Michael W. WEINER, MD

University of California at San Francisco (UCSF)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C DONOHUE (San Diego, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FELDMAN (San Diego, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T.MIDDLETON (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S.RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

* Organizing Committee Member

CTAD 2022 Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Reisa Sperling MD, Ph.D. and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research.

Reisa SPERLING MD

Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, Boston, MA (USA)

Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer's disease (AD) at the pre-symptomatic or "preclinical" stage of AD. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer's Clinical Trial Consortium (ACTC). She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, and recently launched two new prevention trials in the AHEAD 3-45 Study with the ACTC.

Keith JOHNSON MD

Professor of Radiology and Neurology at Harvard Medical School and Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital, Boston, MA (USA)

Dr. Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). He also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women's Hospital as well as a Clinical Associate in Neurology at the MGH. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its Dominantly Inherited Alzheimer Network (DIAN) research initiatives. He oversees the Clinical Brain Positron Emission Tomography (PET) Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders. Dr. Johnson also maintains an Internet teaching atlas of neuroimaging known as the Whole Brain Atlas. His major research interests include the early diagnosis and treatment monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies.

Keynotes

"The Current and Future State of AD plasma biomarkers"

Kaj Blennow , MD, PhD

Academic Chair in Clinical Neurochemistry, University of Gothenburg, Head of the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Gothenburg, Sweden

Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. His main research interest is CSF and blood biomarkers for Alzheimer's disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in clinical trials. Dr. Blennow has published more than 1700 original research papers and review articles in peer-reviewed journals, with more than 110.000 citations, and he has an H-index of 151. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer's Association QC program for CSF and blood biomarkers.

"Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities"

Suzanne Craft, PhD

Professor in Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Dr. Suzanne Craft received her Ph.D. from the University of Texas at Austin, and then completed fellowships at Boston University and Harvard Medical School. She has been a faculty member at Washington University in St. Louis and at the University of Washington. In 2012, she joined the faculty at Wake Forest School of Medicine, where she is Professor of Medicine, and Founding Director of the National Institute on Aging-funded Wake Forest Alzheimer's Disease Research Center. Dr. Craft has served as a member of the Alzheimer's Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer's Clinical Trial Consortium. Dr. Craft's research program investigates the role of metabolic disorders in the development of Alzheimer's disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer's disease. She led a ground-breaking multi-site trial of intranasal insulin for the treatment of Alzheimer's disease that was funded by the National Alzheimer's Project Act. She has received a prestigious Zenith Award from the Alzheimer's Association and a National Institute of Health MERIT award for research excellence. Her work has been featured in HBO's Emmy-award winning series "The Alzheimer's Project: Momentum in Science", in the New York Times and Time magazine, as well as on BBC Newshour, and PBS Newshour.

Keynotes

"Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions"

Miia Kivipelto, MD, PhD

Professor in Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and Director of Research and Development at Karolinska University Hospital, Stockholm (Sweden)

Miia Kivipelto is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director of Research & Development at Theme Aging and Inflammation and Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (340+ publications, H-index 78) and she has received numerous prestigious awards. Dr. Kivipelto's translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer's disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-

"Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease"

Roger Nitsch, MD

CEO and President Neurimmune, Schlieren (Switzerland)

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer's disease research. He is a Potamkin Prize winner and Member of the German Academy of Sciences and served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich. Roger holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.

ONSITE PROGRAM

in San Francisco
Available via livestream
on the CTAD22
digital platform

Program at a glance

Tuesday, NOVEMBER 29

4.00 p.m Opening Ceremony and CTAD Lifetime Achievement Award

4.30 p.m KEYNOTE 1: Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities

4.50 p.m Lecanemab Phase 3 Topline Results

6.30 p.m CTAD Welcome Reception
with the support of the Alzheimer's Association ALZHEIMER'S ASSOCIATION

Wednesday, NOVEMBER 30

8.00 a.m Welcome coffee - Poster Walking Tour

9.00 a.m KEYNOTE 2: Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions

9.20 a.m SYMPOSIUM 1: CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials

10.00 a.m Coffee break and poster session

10.30 a.m LATE BREAKING ORAL COMMUNICATIONS

11.00 a.m ORAL COMMUNICATIONS

12.15 p.m Lunch and poster sessions

1.20 p.m SYMPOSIUM 2: Decentralization Approaches for Clinical Trials on Alzheimer's Disease

2.00 p.m ORAL COMMUNICATIONS' FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging

3.00 p.m LATE BREAKING COMMUNICATIONS

3.45 p.m Coffee break and poster session

4.15 p.m Topline Results of Phase III GRADUATE I & II Confirmatory Trials with Subcutaneous Gantenerumab

Thursday, DECEMBER 1

8.00 a.m Welcome coffee - Poster Walking Tour

9.00 a.m KEYNOTE 3: The Current and Future State of AD plasma biomarkers

9.20 a.m Anti Amyloid Phase 3 results: A CTAD open discussion

9.50 a.m ORAL COMMUNICATIONS' FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions

10.55 a.m Coffee break and poster session

11.20 a.m Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results

12.00 p.m LATE BREAKING ORAL COMMUNICATIONS

12.30 p.m Lunch and poster sessions

1.30 p.m ORAL COMMUNICATIONS

2.30 p.m ROUNDTABLE 1: Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments

3.00 p.m ORAL COMMUNICATIONS

4.00 p.m Coffee break and poster session

4.30 p.m LATE BREAKING ORAL COMMUNICATIONS

Friday, DECEMBER 2

8.00 a.m Welcome coffee - Poster Walking Tour

9.00 a.m KEYNOTE 4: Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease

9.20 a.m LATE BREAKING ORAL COMMUNICATIONS

10.20 a.m Coffee break and poster session

10.45 a.m ROUNDTABLE 2: The Alzheimer's disease Patient Pathway from a sex and gender lens

11.15 a.m ORAL COMMUNICATIONS' FOCUS SESSION: Interim or preliminary data and study design

12.05 p.m Lunch and poster sessions

1.05 p.m ORAL COMMUNICATIONS

1.35 a.m ORAL COMMUNICATIONS' FOCUS SESSION: Clinical Trials Phase 1 Results

2.05 p.m ORAL COMMUNICATIONS

3.05 p.m Coffee break and poster session

3.35 p.m LATE BREAKING ORAL COMMUNICATION

3.50 p.m ORAL COMMUNICATIONS

Tuesday, NOVEMBER 29

4.00 p.m

Opening Ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research

Presented to Reisa Sperling MD, and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research

Introduction by Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA),* Jacques Touchon, *Montpellier University, Montpellier (France),* Bruno Vellas, *Gerontopole, Toulouse University, Toulouse (France),* Mike Weiner, *UCSF, San Francisco, CA (USA)*

4.30 p.m

KEYNOTE 1

Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities

Suzanne Craft, *Wake Forest University School of Medicine, Winston-Salem, NC (USA)*

4.50 p.m

Lecanemab Phase 3 Topline Results

6.30 p.m

CTAD Welcome Reception with the support of the Alzheimer's Association

ALZHEIMER'S ASSOCIATION

7.30 p.m

End of the Conference Day

Wednesday, NOVEMBER 30

08.00 a.m Welcome coffee - Poster Walking Tour

9.00 a.m

KEYNOTE 2

Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions

Miia Kivipelto, *Karolinska Institutet, Center for Alzheimer Research, Karolinska University Hospital, Stockholm (Sweden)*

9.20 a.m

SYMPOSIUM 1

CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials

Chair: Kaj Blennow, University of Gothenburg, Gothenburg (Sweden)

Presentation 1: Relationship between blood plasma and CSF measures of Aβ 42/40, tau, and NfL species for tracking drug effects in clinical trials of Alzheimer's disease

Randall J. Bateman, *Washington University School of Medicine, St. Louis, MO (USA)*

Presentation 2: Consideration and use of AT(N) blood-based biomarkers for community screening

Michelle M. Mielke, *Wake Forest University School of Medicine, Winston-Salem, NC (USA)*

Presentation 3: Implementation of plasma biomarkers into clinical practice and trials

Oskar Hansson, *Lund University, Lund (Sweden)*

10.00 a.m Coffee break and poster session

10.30 a.m

LATE BREAKING ORAL COMMUNICATIONS

10.30 a.m

LB1 - Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials

Keith Johnson [1], Aaron Schultz [1], Robert Rissman [2], Oliver Langford [2], Emma Thibault [1], Matthew Meyer [3], Kristopher Kirmess [3], Michael Irizarry [4], Jin Zhou [4], Michael Donohue [2], Rema Raman [2], Paul Aisen [2], Reisa Sperling [5,1], Ahead 3-45 Study Team [6]

[1]Massachusetts General Hospital - Boston (United States), [2]University of Southern California - San Diego (United States), [3]C2N Diagnostics - St. Louis (United States), [4]Eisai - Nutley (United States), [5]Brigham and Women's Hospital - Boston (United States), [6]ACTC - Many Sites (United States)

10.45 a.m

LB2 - Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD

Robert Rissman [1,2], Oliver Langford [2], Michael Donohue [2], Rema Raman [2], Sara Abdel-Latif [2], Matthew Meyer [3], Kristopher Kirmess [3], Joel Braunstein [3], Michael Irizarry [4], Keith Johnson [5], Paul Aisen [2], Reisa Sperling [6], Team Ahead 3-45 Study [7]

[1]UC San Diego - La Jolla, Ca (United States), [2]University of Southern California - San Diego, Ca (United States), [3]C2N Diagnostics - St. Louis, Mo (United States), [4]Eisai - Indianapolis, In (United States), [5]Massachusets General Hospital, Harvard University - Boston, Ma (United States), [6]Brigham and Woman's Hospital, Harvard - Boston, Ma (United States), [7]ACTC - San Diego, Ca (United States)

11.00 a.m

ORAL COMMUNICATIONS

11.00 a.m

OC1 - ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity

Johannes Streffer [1,2], Julien Mermoud [1], Olivier Sol [1], Marija Vukicevic [1], Emma Fiorini [1], Eva Gollwitzer [1], Valérie Hliva [1], David Hickman [1], Julian Gray [1], Piergiorgio Donati [1], Maria Pilar Lopez Deber [1], Julien Rongère [1], Andrea Pfeifer [1], Marie Kosco-Vilbois [1], Philip Scheltens [3]

[1]AC Immune SA - Lausanne (Switzerland), [2]University of Antwerp - Antwerp (Belgium), [3]VUMC - Amsterdam (The Netherlands)

11.15 a.m

OC2 - Results of a Phase 2/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) inhibitor Irsenontrine (E2027) in Subjects With Dementia With Lewy Bodies

Michael Irizarry [1], Robert Lai [2], Steven Hersch [1], Kate Pinner [2], Shobha Dhadd a [1], Lynn Kramer [1]

[1]Eisai Inc. - Nutley (United States), [2]Eisai Ltd. - Hattfield (United Kingdom)

Wednesday, NOVEMBER 30

11.30 a.m

OC3 - An Update on Interim Data for the First Tau Aggregation Inhibitor – Hydromethylthionine mesylate (HMTM)

Bjoern Schelter[1,2]
[1]TauRx Therapeutics Ltd - Aberdeen (United Kingdom), [2]University of Aberdeen - Aberdeen (United Kingdom)

11.45 a.m

OC4 - Janssen Simoa Plasma p217+tau assay as a precision prescreening tool in Autonomy Ph2 anti-tau monoclonal Ab trial in early Alzheimer's Disease

Gallen Triana-Baltzer[1], Ziad Saad [1], Setareh Moughadam [1], Randy Slemmon [1], Mary Quiceno [1], David Henley [1], Hartmuth Kolb [1]
[1]Janssen Research & Development - San Diego (United States)

12.00 p.m

OC5 - Long term and economic outcomes for mirtazapine and carbamazepine versus placebo: new data from the SYMBAD RCT

Sube Banerjee On Behalf Of The Symbad Group [1]
[1]University Of Plymouth - Plymouth (United Kingdom)

12.15 p.m

Lunch break and poster session

1.20 p.m

SYMPOSIUM 2

Decentralization Approaches for Clinical Trials on Alzheimer's Disease

Chair: Holly Massett, National Institute on Aging – Bethesda, MD (United States)

Presentation 1: Remote assessments in a follow-on study from TRAILBLAZER-ALZ
Jessica Langbaum, *Banner Alzheimer's Institute - Phoenix, AZ (United States)*

Presentation 2: Effects of supervision on cognitive and functional assessment outcomes
Paul Maruff, *CogState - Melbourne (Australia)*

Presentation 3: Decentralization approaches in TRAILBLAZER-ALZ 3
Roy Yaari, *Eli Lilly and Company – Indianapolis, IN (United States)*

Presentation 4: Investigator experience in a decentralized clinical trial on Alzheimer's Disease
Ralph Lee, *Irvine Clinical Research – Irvine, CA (United States)*

2.00 p.m

ORAL COMMUNICATIONS' FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging

2.00 p.m

OC6 - Combination of regional flortaucipir quantification and event-based modeling in clinical trial analyses

Ixavier Higgins [1], Amanda Morris [1], John Sims [1], Mark Mintun [1], Sergey Shcherbinin [1]
[1]Eli Lilly and Company - Indianapolis (United States)

2.10 p.m

OC7 - Longitudinal Tau PET increase is highest in brain regions with strongest functional connectivity to regions with most NFT at Baseline: An independent validation

Ziad S. Saad [1], Ritobrato Datta [1], Christopher Rowe [2], Hartmuth C. Kolb [1]
[1]Janssen R&D, Johnson & Johsnon - San Diego (United States), [2]Austin Health and University of Melbourne - Melbourne (Australia)

2.20 p.m

OC8 - Individualised tau-PET measures might be superior to group level measures when determining change in tau deposition over time in Alzheimer's disease

Antoine Leuzy [1], Alexa Pichet-Binette [1], Jacob W. Vogel [2], Gregory Klein [3], Edilio Borroni [3], Matteo Tonietto [3], Olof Strandberg [1], Niklas Mattsson-Carlgren [1], Sebastian Palmqvist [1], Erik Stomrud [1], Rik Ossenkoppele [1], Ruben Smith [1], Oskar Hansson [1]
[1]Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund (Sweden), [2]Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia (United States), [3]F. Hoffmann-La Roche Ltd, Basel (Switzerland)

Wednesday, NOVEMBER 30

2.30 p.m

OC9 - Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum

Alexis Moscoso [1], Fiona Heeman [1], Valle Camacho [2], Martijn Van Essen [3], Michel J Grothe [4], Li Lin [5], Ismini Mainta [6], Federica Ribaldi [7], Michael D Devous [8], Michael J Pontecorvo [8], Giovanni B Frisoni [7], Valentina Garibotto [7], Michael Schöll [1]

[1]Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), [2]Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), [3]Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), [4]Movement Disorders Group, Institute of Biomedicine of Seville-IBiS, Seville, Spain. - Sevillla (Spain), [5]Department of radiology, the third affiliated hospital of sun yat-sen university. - Guangzhou (China), [6]Division of Nuclear Medicine, Geneva University Hospitals, Geneva, Switzerland. - Genève (Switzerland), [7]Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), [8]Avid Radiopharmaceuticals, Philadelphia, PA, USA - Philadelphia (United States)

2.40 p.m

OC10 - Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy

Gerald Novak [1], Ziad Saad [2], David Scott [3], Chi Udeh-Momoh [4], Luc Bracoud [5], Craig Ritchie [6], Lefkos Middleton [7]

[1]Janssen R&D - Titusville, Nj (United States), [2]Janssen R&D - La Jolla, Ca (United States), [3]Clario (formerly Bioclinica) - San Mateo, Ca (United States), [4]Imperial College - London (United Kingdom), [5]Clario (formerly Bioclinica) - Lyon (France), [6]University of edinburgh - Edinburgh (United Kingdom), [7]Imperial College - Edinburgh (United Kingdom)

2.50 p.m

OC11 - Amyloid IQ quantification strongly agrees with both histopathology and visual reads across multiple amyloid tracers

Alex Whittington [1], Santiago Bullich [2], Lily Porat [1], Roger Gunn [1]

[1]Invicro - London (United Kingdom), [2]Life Molecular Imaging - Berlin (Germany)

3.00 p.m

LATE BREAKING ORAL COMMUNICATIONS

3.00 p.m

LB3 - TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease

Stephen Salloway [1], Elly Lee [2], Michelle Papka [3], Andrew Pain [4], Ena Oru [4], Margaret B. Ferguson [4], Hong Wang [4], Michael Case [4], Ming Lu [4], Emily C. Collins [4], Dawn Brooks [4], John Sims [4]

[1]Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital - Providence (United States), [2]Irvine Clinical Research - Irvine (United States), [3]The Cognitive and Research Center of New Jersey LLC - Springfield (United States), [4]Eli Lilly and Company - Indianapolis (United States)

3.15 p.m

LB4 - CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer's disease

Kanta Horie [1,2], Gemma Salvadó [3], Nicolas Barthélemy [1], Yan Li [1], Benjamin Saef [1], Charlie Chen [1], Hong Jiang [1], Brian Gordon [1], Tammie Benzinger [1], David Holtzman [1], Suzanne Schindler [1], Oskar Hansson [3,4], Randall Bateman [1]

[1]Washington University School of Medicine - St. Louis (United States), [2]Eisai Inc. - Nutley (United States), [3]Lund University - Lund (Sweden), [4]Skåne University Hospital - Malmö (Sweden)

3.30 p.m

LB5 - Top-line Results from the 2-Year Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT)

Kristine Yaffe [1], Eric Vittinghoff [1], Sascha Dublin [2], Carrie Peltz [1], Lynn Fleckenstein [2], Dori Rosenberg [2], Deborah Barnes [1], Bejamin Balderson [2], Eric Larson [3]

[1]University of California, San Francisco - San Francisco, Ca (United States), [2]Kaiser Permanente Washington Health Research Institute - Seattle, Wa (United States), [3]University of Washington - Seattle, Wa (United States)

3.45 p.m — Coffee break and poster session

4.15 p.m

Topline Results of Phase III GRADUATE I & II Confirmatory Trials with Subcutaneous Gantenerumab

5.15 p.m — End of the Conference Day

Thursday, DECEMBER 1

08.00 a.m — Welcome coffee - Poster Walking Tour

9.00 a.m — **KEYNOTE 3**

The Current and Future State of AD plasma biomarkers

Kaj Blennow, *University of Gothenburg, and Sahlgrenska University Hospital - Gothenburg (Sweden)*

9.20 a.m — **Anti Amyloid Phase 3 results: A CTAD open discussion**

Maria Carrillo[1], David Knopman[2], Lefkos Middleton[3], Ron Petersen[2]

[1] Alzheimer's Association - Chicago, IL (United States), [2] Mayo Clinic - Rochester, MN (United States), [3] Imperial College - London (United Kingdom)

9.50 a.m — **ORAL COMMUNICATIONS' FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions**

Chair: Howard Fillit, *Alzheimer's Drug Discovery Foundation, New York, NY (USA)*

9.55 a.m — **OC12 - Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?**

Carl Cotman [1], Howard Feldman [2], Andrea Lacroix [2], Aladdin Shadyab [2], Diane Jacobs [2], David Salmon [2], Ron Thomas [2], Shelia Jin [2], Judy Pa [2], Jeffrey Katula [3], Robert Rissman [4], James Brewer [2], Youngkyoo Jung [5], Jing Zhang [2], Laura Baker [6]

[1]UCI (United States), [2]UCSD (United States), [3]Wake Forest University (United States), [4]USC (United States), [5]UC Davis (United States), [6]Wake Forest University School of Medicine (United States)

10.10 a.m — **OC13 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (STOMP-AD) – Pilot Study Results on Central Nervous System Penetrance and Alzheimer's Disease Biomarkers**

Mitzi Gonzales [1], Valentina Garbarino [1], Tiffany Kautz [1], Ronald Petersen [2], Tamara Tchkonia [2], James Kirkland [2], Suzanne Craft [3], Sudha Seshadri [1], Nicolas Musi [1], Miranda Orr [3]

[1]UT Health San Antonio - San Antonio (United States), [2]Mayo Clinic - Rochester (United States), [3]Wake Forest School Of Medicine - Winston-Salem (United States)

10.25 a.m — **OC14 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients**

Ronald Van Der Geest [1], Anastasia Lili [1], Oscar Van Loosbroek [1], Andreia Almeida [1], Marlies Oosthoek [2], Charlotte Teunissen [2], Sietske Sikkes [3], Everard Vijverberg [2]

[1]Treeway TW001AD BV - Tilburg (Netherlands), [2]Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), [3]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)

10.40 a.m — **OC15 - Protein Biomarkers in Autosomal Dominant Alzheimer's Disease Cerebrospinal Fluid Identify Early Changes in Brain Glucose Metabolism and the Matrisome**

Shijia Bian [1], E. Kathleen Carter [1], Rafi Haque [1], Caroline Watson [1], Brian Gordon [2], Lingyan Ping [1], Duc Duong [1], Michael Epstein [1], James Lah [1], Blaine Roberts [1], Anne Fagan [2], Nicholas Seyfried [1], Allan Levey [1], Erik Johnson [1]

[1]Emory University - Atlanta (United States), [2]Washington University - St. Louis (United States)

10.55 a.m — Coffee break and poster session

11.20 a.m — **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**

Presentation: Daniel Lee [2], Mary Slomkowski [2], Nanco Hefting [3], Dalei Chen [2], Klaus Larsen [3], Eva Kohegyi [2], Mary Hobart [2], Jeffrey Cummings [4]

[1]Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St. Louis, Missouri (United States), [2]Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), [3]H. Lundbeck A/S - Valby, Copenhagen (Denmark), [4]Chambers-Grundy Center for Transformative Neuroscience at School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) - Las Vegas, Nevada (United States)

Panel discussion

Thursday, DECEMBER 1

12.00 p.m

LATE BREAKING ORAL COMMUNICATIONS

12.00 p.m

LB6 - Two-year prognostic utility of plasma p217+tau in the Alzheimer continuum

Azadeh Feizpour [1,2], Vincent Doré [2,3], James D. Doecke [4], Ziad S. Saad [5], Gallen Triana-Baltzer [5], Natasha Krishnadas [1,2], Christopher Fowler [1], Larry Ward [1], Ralph N. Martins [6,7], Colin L. Masters [1], Victor L. Villemagne [2,8], Jurgen Fripp [4], Hartmuth C. Kolb [5], Christopher C. Rowe [2,1,9]

[1]The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia - Melbourne (Australia), [2]Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia - Melbourne (Australia), [3]The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia - Melbourne (Australia), [4]The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia - Brisbane (Australia), [5]Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA - San Diego (United States), [6]Edith Cowan University - Perth (Australia), [7]McCusker Alzheimer's Research Foundation, Nedlands, - Perth (Australia), [8]Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA - Pittsburgh (United States), [9]Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia - Melbourne (Australia)

12.15 p.m

LB7 - ALZ-NET: Using Real World Evidence to Define the Future of Alzheimer's Treatment and Care

Maria Carrillo [1], Gil Rabinovici [2], Michael Rafii [3]

[1]Alzheimer's Association - Chicago (United States), [2]Memory and Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco - San Francisco (United States), [3]Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States)

12.30 p.m Lunch break and poster session

1.30 p.m

ORAL COMMUNICATIONS

1.30 p.m

OC16 - Leveraging novel technologies to design and implement more patient focused clinical trials

Dave Miller [1] *[1]Unlearn.AI - Berkeley (United States)*

1.45 p.m

OC17 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?

Rik Ossenkoppele [1], Alexa Pichet Binette [1], Colin Groot [1], Reisa Sperling [2], Colin Masters [3], Wiesje Van Der Flier [4], William Jagust [5], Petersen Ronald [6], Clifford Jack [6], Oskar Hansson [1]

[1]Lund University - Lund (Sweden), [2]MGH - Boston (United States), [3]The Florey Institute Of Neuroscience And Mental Health Melbourne Victoria Australia - Parkville (Australia), [4]Amsterdam University Medical Center - Amsterdam (Netherlands), [5]UC Berkeley - Berkeley (United States), [6]Mayo Clinic - Rochester (United States)

2.00 p.m

OC18 - Plasma NT1-tau correlates with age and cognitive decline in two large Down syndrome cohorts

Andrew M. Stern [1], Kathryn L. Van Pelt [2], Lei Liu [1], Amirah K. Anderson [1], Beth Ostaszewski [1], Dennis J. Selkoe [1], Frederick Schmitt [2], Elizabeth Head [3]

[1]Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston, MA (United States), [2]Sanders-Brown Center For Aging, Department Of Neurology, University Of Kentucky - Lexington, KY (United States), [3]Department Of Pathology And Laboratory Medicine, University Of California, Irvine - Irvine, CA (United States)

2.15 p.m

OC19 - Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle burden

Gemma Salvadó [1], Rik Ossenkoppele [1,2], Nicholas J Ashton [3,4,5], Thomas G Beach [6], Geidy E Serrano [6], Gwendlyn Kollmorgen [7], Henrik Zetterberg [3,8,9,10], Shorena Janelidze [1], Kaj Blennow [3], Oskar Hansson [1,11]

[1]Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University - Lund (Sweden), [2]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center - Amsterdam (Netherlands), [3]Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), [4]Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London - London (United Kingdom), [5]NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation - London (United Kingdom), [6]Banner Sun Health Research Institute - Sun City (United States), [7]Roche Diagnostics GmbH - Penzberg (Germany), [8]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), [9]Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), [10]UK Dementia Research Institute at UCL - London (United Kingdom), [11]Memory Clinic, Skåne University Hospital - Malmö (Sweden)

Thursday, DECEMBER 1

2.30 p.m

ROUNDTABLE 1

Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments

Chair: **Niranjan Bose,** *Gates Ventures, Seattle, WA (United States)*

Discussants: Howard Fillit, *Alzheimer's Drug Discovery Foundation (ADDF), New York City, NY (United States);* Laurence Barker, *Partner in the Dementia Discovery Fund (DDF), London (United Kingdom);* Philip Scheltens, *LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam (University Medical Centre Amsterdam, Amsterdam (The Netherlands)*

3.00 p.m

ORAL COMMUNICATIONS

3.00 p.m

OC20 - Systemic inflammation and reduced cerebral Aβ clearance triggered by pancreatic amylin

Florin Despa [1], Nirmal Verma [1], Edric Winford [1], Peter Nelson [1], Gregory Jicha [1], Larry Goldstein [1], Claire Troakes [2], Henrik Zetterberg [3], John Hardy [3], Tammaryn Lashley [3]

[1]University Of Kentucky - Lexington (United States), [2]King's College London - London (United Kingdom), [3]Dementia Research Institute at UCL - London (United Kingdom)

3.15 p.m

OC21 - Prazosin for Agitation in Alzheimer's Disease: PEACE-AD

Elaine Peskind [1], Murray Raskind [2], Ronald Thomas [3], Gregory Jicha [4], Neela Patel [5], Amy Pierce [6], Sharon Brangman [7], Mary Sano [8], Jeffrey Kaye [6], Miranda Lim [6], Michael Au-Yeung [6], Michelle Herman [9], Gabriel Leger [9], Karen Messer [9], Howard Feldman [9]

[1]VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC), Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), [2]VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC) and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), [3]Departments of Family Medicine and Neurosciences, University of California San Diego - La Jolla (United States), [4]Department of Neurology, University of Kentucky - Lexington (United States), [5]Department of Family and Community Medicine, UT Health San Antonio - San Antonio (United States), [6]Department of Neurology, OHSU School of Medicine - Portland (United States), [7]Department of Geriatrics, SUNY Upstate Medical University - Syracuse (United States), [8]Department of Psychiatry, Mount Sinai School of Medicine - New York (United States), [9]Department of Neurosciences, University of California San Diego - La Jolla (United States)

3.30 p.m

OC22 - Demographic Analysis of Industry Sponsored Alzheimer's DiseaseTrial Populations in the United States

Stephen Peroutka [1] - *[1]PPD, Part Of Thermo Fisher Scientific – Carmel, CA (United States)*

3.45 p.m

OC23 - Plasma Biomarker Findings from the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

Eric M. Reiman [1], Francisco Lopera [2], Silvia Rios-Romenets [2], Courtney Schiffman [3], Derrek Hibar [3], Gwendlyn Kollmorgen [4], Margarita Giraldo [2], Natalia Acosta [2], Alejandro Espinosa [2], Gustavo Villegas [2], Claudia Muñoz [2], Laura Serna [2], Karina Herrera [2], Yi Su [1], Robert Alexander [1]

[1]Banner Alzheimer's Institute - Phoenix, Arizona (United States), [2]Neurosciences Group of Antioquia, University of Antioquia - Medellín (Colombia), [3]Genentech, Inc., - South San Francisco, Ca (United States), [4]Roche Diagnostics GmbH - Mannheim (Germany)

4.00 p.m

Coffee break and poster session

4.30 p.m

LATE BREAKING ORAL COMMUNICATIONS

4.30 p.m

LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer's Disease (AD)

Stephen Macfarlane [1], Timo Grimmer [2], Terence O'brien [3], Edward Hammond [4], Walter Kaufmann [4], Emmanuel Fadiran [4], Christopher Missling [4]

[1]Hammoncare - Melbourne (Australia), [2]THU Munich - Munich (Germany), [3]Monash University, Alfred Health - Melbourne (Australia), [4]Anavex Life Sciences - New York (United States)

4.45 p.m

LB9 - Higher sensitivity amyloid-PET detection of the earliest focal beta-amyloid accumulation using spatial extent

Michelle E. Farrell [1], Emma G. Thibault [1], J. Alex Becker [1], Julie C. Price [1], Kuang Gong [1], Aaron P. Schultz [1], Michael J Properzi [1], Rachel F Buckley [1,2], Heidi I.l. Jacobs [1], Bernard J. Hanseeuw [1,3], Reisa A. Sperling [1,2], Keith A. Johnson [1,2]

[1]Massachusetts General Hospital - Boston, Ma (United States), [2]Brigham & Women's Hospital - Boston, Ma (United States), [3]Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Brussels (Belgium)

Thursday, DECEMBER 1

5.00 p.m

LB10 - Sample size estimates for preclinical AD intervention trials based on Wisconsin Registry for Alzheimer's Prevention Longitudinal PET amyloid, plasma P-tau217, and cognitive assessment data

Rebecca Langhough Koscik [1], Derek Norton [1], Tobey Betthauser [1], Lianlian Du [1], Erin Jonaitis [1], Karly Cody [1], Bruce Hermann [1], Kimberly Mueller [1], Rick Chappell [1], Bradley Christian [1], Shorena Janelidze [1], Niklas Mattsson-Carlgren [1], Oskar Hansson [1], Sterling Johnson [1]

[1]University of Wisconsin SMPH - Madison (United States)

5.15 p.m

LB11 - Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease: Results From the PEGASUS Trial

Steven E. Arnold [1,2], Newman Knowlton [3], Victoria J. Williams [4], Jeffrey M. Burns [5], Monica Crane [6], Alison J. Mcmanus [1], Sanjeev N. Vaishnavi [7], Zoe Arvanitakis [8], Judith Neugroschl [9], Karen Bell [10], Bianca A. Trombetta [1], Becky C. Carlyle [11], Pia Kivisäkk [12,2], Rudolph E. Tanzi [13,14], Kent Leslie [15,16]

[1]Department of Neurology, Massachusetts General Hospital, Boston, MA, USA - Boston (United States), [2]Harvard Medical School, Boston, MA, USA - Boston (United States), [3]Pentara Corporation, Millcreek, UT, USA - Millcreek (United States), [4]Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA - Madison (United States), [5]University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA - Kansas City (United States), [6]Genesis Neuroscience Clinic, Knoxville, TN, USA - Knoxville (United States), [7]Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA - Philadelphia (United States), [8]Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA - Chicago (United States), [9]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA - New York (United States), [10]Department of Neurology, Columbia University, New York, NY, USA - New York (United States), [11]Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, England, United Kingdom - England (United Kingdom), [12]Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 2Harvard Medical School, Boston, MA, USA - Boston (United States), [13]Harvard Medical School, Boston, MA, USA - Boston (United Kingdom), [14]Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University, Boston, MA, USA - Boston (United States), [15]Amylyx Pharmaceuticals, Inc., Cambridge, MA, USA - Cambridge (United States), [16]Present address: Division of Biology and Biological Engineering Graduate Program, California Institute of Technology, Pasadena, CA, USA - Pasadena (United States)

5.30 p.m

End of the Conference Day

Friday, DECEMBER 2

08.00 a.m Welcome coffee - Poster Walking Tour

9.00 a.m

KEYNOTE 4

Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease

Roger Nitsch, *Neurimmune, Schlieren (Switzerland)*

9.20 a.m

LATE BREAKING ORAL COMMUNICATIONS

9.20 a.m

LB12 - Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients With Symptoms of Cognitive Impairment

Joel Braunstein [1], Mark Monane [1], Kim Johnson [2], B. Joy Snider [3], Raymond Scott [4], Jonathan Drake [5], Daniel Jacobs [6], Julia Ortega [1], Joni Henderson [1], Tim West [1]

[1]C2N Diagnostics - St Louis (United States), [2]Duke University - Durham (United States), [3]Washington University - St Louis (United States), [4]Georgetown University - Washington (United States), [5]Lifespan - Providence (United States), [6]Neurological Services of Orlando - Orlando (United States)

9.35 a.m

LB13 - Phase 1 pharmacokinetic and CNS target engagement properties of the orally administered O-GlcNAcase inhibitor ASN51 in humans

Ryan Schubert [1], Rolf Pokorny [1], Bruno Permanne [1], Pearl Fang [1], Vanessa Teachout [1], Maud Nény [1], Solenne Ousson [1], Jennifer Hantson [1], Astrid Sand [1], Ruhi Ahmed [1], Manfred Schneider [1], Jean-Francois Stallaert [1], Anna Quattropani [1], Eric Yuen [1], Dirk Beher[1]

[1]Asceneuron, Lausanne (Switzerland)

9.50 a.m

LB14 - Analysis of 15 software pipelines for validation of [18F]florbetaben PET quantitation

Aleksandar Jovalekic [1], Nuria Roe-Vellve [1], Norman Koglin [1], Mariana Lagos Quintana [1], Aaron Nelson [2], Markus Diemling [3], Johan Lilja [3], Juan Pablo Gomez Gonzalez [4], Vincent Dore [5], Pierrick Bourgeat [5], Alex Whittington [6], Roger Gunn [6], Andrew Stephens [1], Santiago Bullich [1]

[1]Life Molecular Imaging - Berlin (Germany), [2]MIM Software - Cleveland (United States), [3]Hermes Medical Solutions - Stockholm (Sweden), [4]QuBiotech - A Coruna (Spain), [5]CSIRO - Brisbane (Australia), [6]Invicro - London (United Kingdom)

10.05 a.m

LB15 - Results from a clinical Study of an Anti-Galectin-3 Monoclonal antibody in Patients with Moderate to Severe Alzheimer's Disease

Dongxu Sun [1], George Haig [1], Suhail Rasool [1]

[1]Truebinding Inc - Foster City (United States)

10.20 a.m Coffee break and poster session

10.45 a.m

ROUNDTABLE 2

The Alzheimer's disease Patient Pathway from a sex and gender lens

Chair: Frances Catherine Quevenco [1,2]

Discussants: Maria Carmela Tartaglia [3], Heather Snyder [4], Phyllis Ferrell [5], Pernille Poulsen [6], Antonella Santuccione Chadha [7,2]

[1]Roche (Switzerland), [2]Women's Brain Project (Switzerland), [3]University Of Toronto (Canada), [4]Alzheimer's Association (United States), [5]Eli Lilly (United States), [6]Novo Nordisk (Denmark), [7]Altoida (United States)

11.15 a.m

ORAL COMMUNICATIONS' FOCUS SESSION: Interim or preliminary data and study design

11.15 a.m

OC24 - Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Kaya Jordan [1], Kennedy Mahdavi [1,2], Jonathan Haroon [1], Elisabeth Rindner [1], Margaret Zielinski [1], Victoria Venkatraman [1,2], Sergio Becerra [2], Dayan Goodenowe [3], Clarence Ahlem [4], Christopher Reading [4], Joseph Palumbo [4], Bijan Pourat [5], Sheldon Jordan [1,2]

[1]The Regenesis Project - Santa Monica (United States), [2]Synaptec Network - Santa Monica (United States), [3]Prodrome Sciences USA LLC - Temecula (United States), [4]Biovie Inc. - Carson City (United States), [5]Pourat MD - Beverly Hills (United States)

Friday, DECEMBER 2

11.25 a.m

OC25 - HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer's disease with AGB101: Baseline Tau and MRI imaging characteristics

Richard Mohs [1], Sharon Rosenzweig-Lipson [1], Arnold Bakker[2], Elizabeth Chang[2], Nisha Rani[2], Russell Barton[1], Michela Gallagher[1,2]
[1]AgeneBio, Inc - Baltimore (United States), [2]Johns Hopkins University - Baltimore (United States)

11.35 a.m

OC26 - Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy

Jan Johansson [1], Hussein Yassine [2], Danny Michaelson [3], Henrik Zetterberg [4], Jeffrey Cummings [5], Bengt Winblad [6]
[1]Artery Therapeutics, Inc. - San Ramon (United States), [2]USC - Los Angeles (United States), [3]Tel Aviv University - Tel Aviv (Israel), [4]U of Gothenburg - Gothenburg (Sweden), [5]U Nevada Las Vegas - Las Vegas (United States), [6]Karolinska Insitute - Stockholm (Sweden)

11.45 a.m

OC27 - Significant Effects of Oral ALZ-801 on Plasma Biomarkers of Alzheimer's Disease: 12-Month Interim Analysis of Phase 2 Biomarker Study in APOE4 Carriers with Early AD

Susan Abushakra[1], John Hey [1], Kaj Blennow [2], Philip Scheltens [3], Jakub Hort [4], Katerina Sheardova [5], Niels Prins [6], Sterre Rutgers [6], Paul Dautzenberg [7], Ladislav Pazdera [8], Patrick Kesslak [1], Aidan Power [1], Martin Tolar [1]
[1]Alzheon Inc. - Framingham, Ma (United States), [2]Gothenburg University, Institute of Neuroscience & Physiology - Molndal (Sweden), [3]Amsterdam University Medical Center - Amsterdam (Netherlands), [4]Charles University Dept. of Neurology - Prague (Czech Republic), [5]St. Anne University Hospital & International Clinical Research Center - Brno (Czech Republic), [6]Brain Research Center - Amsterdam (Netherlands), [7]Brain Research Center - Den Bosch (Netherlands), [8]Vestra Research Clinic - Rychnov Nad Kněžnou (Czech Republic)

11.55 a.m

OC28 - Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease

Nicola Spotorno [1], Olof Strandberg [1], Geraline Vis [2,3], Erik Stomrud [1], Markus Nilsson [2,4], Oskar Hansson [1]
[1]Clinical Memory Research Unit, Department Of Clinical Sciences, Lund University - Lund (Sweden), [2]Diagnostic Radiology, Institution For Clinical Sciences, Lund University - Lund (Sweden), [3] Memory Clinic, Skåne University Hospital - Malmö (Sweden), [4]Memory Clinic, Skåne University Hospital - Malmö (Sweden)

12.05 p.m

Lunch break and poster sessions

1.05 p.m

ORAL COMMUNICATIONS

1.05 p.m

OC29 - A brief, automated speech-based screener for mild cognitive impairment to support online recruitment at scale

Caroline Skirrow [1], Jack Weston [1], Marton Meszaros [1], Udeepa Meepegama [1], Emil Fristed [1]
[1]Novoic - London (United Kingdom)

1.20 p.m

OC30 - Aβ-structure as Precise Risk Plasma Biomarker for Future Conversion to Alzheimer´s Disease 17 Years in Advance

Klaus Gerwert [1,2]
[1]Ruhr-University Bochum - Bochum (Germany), [2]Center for Protein Diagnostics (ProDi) - Bochum (Germany)

1.35 p.m

ORAL COMMUNICATIONS' FOCUS SESSION: Clinical Trials Phase 1 Results

1.35 p.m

OC31 - NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease

Daniel Mikol [1], Judy Toews [1], Martin Farlow [2], Bruce Lamb [2], George Perry [3], Reisa Sperling [4], Michael Weiner [5], Henrik Zetterberg [6], Jeffrey Cummings [7]
[1]Nervgen - Vancouver (Canada), [2]Indiana University School Of Medicine - Indianapolis (United States), [3]University Of Texas, San Antonio - San Antonio (United States), [4]Harvard Medical School - Cambridge (United States), [5]University Of California, San Francisco - San Francisco (United States), [6]University Of Gothenburg - Gothenburg (Sweden), [7]University Of Nevada, Las Vegas - Las Vegas (United States)

Friday, DECEMBER 2

1.45 p.m

OC32 - Introduction to the Veri-T trial: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP

Peter Ljubenkov [1], Adam Staffaroni [1], Lawren Vandevrede [1], Julio Rojas-Martinez [1], Mary Koestler [1], Anton Porsteinsson [2], Maria B. Pascual [3], Joseph Masdeu [3], Ian Grant [4], David Irwin [5], David Knopman [6], Robert Bowser [7], Murray Grossman [5], Irfan Qureshi [8], Adam Boxer [1]

[1]UCSF Memory and Aging Center - San Francisco (United States), [2]University of Rochester - Rochester (United States), [3]Houston Methodist - Houston (United States), [4]Northwestern University - Chicago (United States), [5]University of Pennsylvania - Philadelphia (United States), [6]Mayo Clinic Rochester - Rochester (United States), [7]Barrow Neurological Institute - Phoenix (United States), [8]Biohaven Pharmaceuticals - New Haven (United States)

1.55 p.m

OC33 - A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer's Disease – Interim Data

Michael Kaplitt [1], Philip Leopold [2], Evan Noch [3], Jana Ivanidze [4], Levi Chazen [4], Ronald Crystal [2], Stephen Kaminsky [2], Haley Bowe [2], Mei Wang [2], Douglas Ballon [4], Jonathan Dyke [4], Dolan Sondhi [2], Sam Gandy [5], Gina Giannantoni-Ibelli [6], Jay Barth [6]

[1]Department of Neurological Surgery, Weill Cornell Medical College - New York (United States), [2]Department of Genetic Medicine, Weill Cornell Medical College - New York (United States), [3]Department of Neurology, Weill Cornell Medical College - New York (United States), [4]Department of Radiology, Weill Cornell Medical College - New York (United States), [5]Departments of Neurology and Psychiatry, Icahn School of Medicine at Mt Sinai - New York (United States), [6]LEXEO Therapeutics, Inc. - New York (United States)

2.05 p.m

ORAL COMMUNICATIONS

2.05 p.m

OC34 - Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample

Chris Edgar [1], Rebecca Amariglio [2], Jordan Barbone [3], Julie Chandler [4], Stephen Coons [5], Michael Donohue [6], William Lenderking [7], Reisa Sperling [8]

[1]Cogstate - London (United Kingdom), [2]Departments of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School - Boston (United States), [3]Cogstate - New Haven (United States), [4]Eli Lilly and Company - Indianapolis (United States), [5]Clinical Outcome Assessment Program, Critical Path Institute - Tucson (United States), [6]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), [7]Patient-centered Research, Evidera - Bethesda (United States), [8]Department of Neurology, Brigham and Women's Hospital - Boston (United States)

2.20 p.m

OC35 - APOE-Targeted Epigenome Therapy for Alzheimer's Disease

Boris Kantor [1,2], Ornit Chiba-Falek [1,3]

[1]Duke University - Durham (United States), [2]CLAIRIgene LLC - Durham (United States), [3]CLAIRIgene - Durham (United States)

2.35 p.m

OC36 - Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

Alexa Pichet Binette [1], Shorena Janelidze [1], Nicholas Cullen [1], Jeffrey L. Dage [2], Randall J. Bateman [3], Henrik Zetterberg [4,5], Kaj Blennow [4], Erik Stomrud [1], Niklas Mattsson-Carlgren [1], Oskar Hansson [1]

[1]Clinical Memory Research Unit, Faculty Of Medicine, Lund University - Lund (Sweden), [2]Department Of Neurology, Indiana University School Of Medicine - Indianapolis (United States), [3]Department Of Neurology, Washington University School Of Medicine - St. Louis (United States), [4]Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), [5]UK Dementia Research Institute, University College London - London (United Kingdom)

2.50 p.m

OC37 - Aducanumab and lecanemab label insoluble, fibrillar, diffusible Aβ aggregates in aqueous extracts of human Alzheimer disease brain

Andrew M. Stern [1], Angela L. Meunier [1], Wen Liu [1], Maria Ericsson [2], Dennis J. Selkoe [2]

[1]Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston (United States), [2]Harvard Medical School Electron Microscopy Core - Boston (United States)

3.05 p.m

Coffee break and poster session

Friday, DECEMBER 2

3.35 p.m

LATE BREAKING ORAL COMMUNICATION

3.35 p.m

LB16 - Phase 1 Preventive Adjuvanted Tau Vaccine, AV-1980R

Lon Schneider [1], Anahit Ghichikyan [2], Robert Alexander [3], Henrik Zetterberg [3], Eric Reiman [3], Duygu Tosun [4], Michael Agadjanyan [2]
[1]USC - Los Angeles (United States), [2]Institute for Molecular Medicine - Huntington Beach (United States), [3]Banner Alzheimer's Institute - Phoenix (United States), [4]University of California San Francisco - San Francisco (United States)

3.50 p.m

ORAL COMMUNICATIONS

3.50 p.m

OC38 - A multimodal clinical and lifestyle intervention induces multiomic systemic effects and improves cognitive outcomes in Alzheimer's disease

Jared C. Roach [1], Lance E. Edens [1], Sophiya Rajbhandari [1], Junko Hara [2], Jennifer Bramen [3, 4], Molly K. Rapozo [5], Cory Funk [1], William R. Shankle [6, 7, 2, 8], Leroy Hood [1]
[1]Institute For Systems Biology - Seattle, Washington (United States), [2]Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian - Newport Beach, California (United States), [3]Pacific Brain Health Center, Pacific Neuroscience Institute - Santa Monica, California (United States), [4]Department of Translational Neurosciences and Neurotherapeutics, Saint John's Cancer Institute - Santa Monica, California (United States), [5]Providence St. Joseph Health - Renton, Washington (United States), [6]Shankle Clinic - Newport Beach, California (United States), [7]Department of Cognitive Sciences, University of California - Irvine, California (United States), [8]EMBIC Corporation - Newport Beach, California (United States)

4.05 p.m

OC39 - Advantages of next generation SupraAntigen® platform liposomal vaccines to immunize against pathological targets of Alzheimer's disease

Marija Vukicevic [1], Emma Fiorini [1], David Hickman [1], Rakel Carpintero [2], Marcela Rincon [2], Maria Pilar Lopez-Deber [2], Maxime Ayer [2], Stefanie Siegert [2], Chiara Babolin [2], Eva Gollwitzer [2], Saskia Delpretti-Anex [2], Piergiorgio Donati [2], Johannes Streffer [2, 3], Andrea Pfeifer [2], Marie Kosco-Vilbois [2]
[1]Ac Immune SA - Lausanne (Switzerland), [2]AC Immune SA - Lausanne (Switzerland), [3]University of Antwerp - Antwerpen (Belgium)

4.20 p.m

OC40 - U-p53AZ in prognostication of early onset Alzheimer's disease up to 6 years in advance of the clinical diagnosis

Simona Piccirella [1], Leander Van Neste [2], Christofer Fowler [3], Colin Masters [3], Jurgen Fripp [4], James D. Doecke [4], Chengjie Xiong [5], Daniela Uberti [6], Paul Kinnon [1]
[1]Diadem SpA - Brescia (Italy), [2]Halixo BV - Hoegaarden (Belgium), [3]The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), [4]The Australian e-Health Research Centre, CSIRO - Herston (Australia), [5]Washington University School of Medicine, Division of Biostatistics - St. Louis (United States), [6]Department of Molecular and Translational Medicine, University of Brescia - Brescia (Italy)

4.35 p.m

OC41 - iWHELD: An RCT of a Novel Digital Non-Pharmacological Intervention to Improve Quality of Life and Reduce Antipsychotics in 741 People Living in Nursing Homes During the COVID-19 Pandemic

Clive Ballard [1], Joanne Mcdermid [1], Adrienne Sweetnam [1]
[1]University of Exeter - Exeter (United Kingdom)

4.50 p.m

OC42 - Making digital measures fit-for-purpose in Alzheimer's trials

Francesca Cormack [1], Jennifer Sorinas [2], Claire Meunier [3]
[1]Cambridge Cognition - Cambridge (United Kingdom), [2]Novartis - Basel (Switzerland), [3]DiMe - San Francisco (United States)

5.05 p.m

End of the Conference Day

Follow us on social media!

@CTADConference
#CTAD22

CTAD Conference

CTAD Alzheimer

Email: ctad@ant-congres.com

www.ctad-alzheimer.com